G. Gallant

493 total citations
21 papers, 374 citations indexed

About

G. Gallant is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Gallant has authored 21 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Gallant's work include Cancer Treatment and Pharmacology (5 papers), Cell death mechanisms and regulation (4 papers) and Cancer therapeutics and mechanisms (3 papers). G. Gallant is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cell death mechanisms and regulation (4 papers) and Cancer therapeutics and mechanisms (3 papers). G. Gallant collaborates with scholars based in Canada, United States and Germany. G. Gallant's co-authors include Hélène Dulude, Stephan Kanzler, Christian Schulz, C.-H. Köhne, Markus Moehler, Tanja Trarbach, Volker Heinemann, Vesna Šneller, Neil A. Hagen and Scott Ernst and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

G. Gallant

21 papers receiving 369 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Gallant Canada	8	192	171	66	55	45	21	374
Jessica Boklan United States	12	215 1.1×	118 0.7×	59 0.9×	20 0.4×	55 1.2×	30	467
Satoshi Ohno Japan	12	260 1.4×	105 0.6×	85 1.3×	47 0.9×	111 2.5×	24	522
Emily K. Thomas United States	11	281 1.5×	89 0.5×	41 0.6×	69 1.3×	69 1.5×	20	527
Benjamin B. Mull United States	11	174 0.9×	132 0.8×	89 1.3×	17 0.3×	49 1.1×	12	410
R. Mauritz Netherlands	9	124 0.6×	130 0.8×	38 0.6×	37 0.7×	33 0.7×	14	427
Cheryl L. Hayden United States	9	179 0.9×	113 0.7×	17 0.3×	28 0.5×	38 0.8×	13	549
Anna Grazia Recchia Italy	16	265 1.4×	166 1.0×	79 1.2×	96 1.7×	22 0.5×	38	653
Chung‐Tai Yue Taiwan	10	338 1.8×	220 1.3×	32 0.5×	101 1.8×	43 1.0×	30	601
Anna Wolska Poland	13	166 0.9×	148 0.9×	205 3.1×	46 0.8×	27 0.6×	29	512
Futoshi Kurimoto Japan	12	188 1.0×	151 0.9×	24 0.4×	26 0.5×	116 2.6×	27	388

Countries citing papers authored by G. Gallant

Since Specialization

Citations

This map shows the geographic impact of G. Gallant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Gallant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Gallant more than expected).

Fields of papers citing papers by G. Gallant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Gallant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Gallant. The network helps show where G. Gallant may publish in the future.

Co-authorship network of co-authors of G. Gallant

This figure shows the co-authorship network connecting the top 25 collaborators of G. Gallant. A scholar is included among the top collaborators of G. Gallant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Gallant. G. Gallant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gallant, G., Hugo Pomares‐Millan, Judy R. Rees, Margaret R. Karagas, & Michael N. Passarelli. (2024). Abstract B001: Urinary bladder cancer incidence and mortality in the United States: 20-year trends and initial impact of the COVID-19 pandemic. Clinical Cancer Research. 30(10_Supplement). B001–B001. 1 indexed citations

Šikić, Branimir I., S. Gail Eckhardt, G. Gallant, et al.. (2011). Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.. Journal of Clinical Oncology. 29(15_suppl). 3008–3008. 33 indexed citations

Pawel, Joachim von, David R. Spigel, Mircea Dediu, et al.. (2010). 進行性NSCLC患者におけるカルボプラチンとパクリタキセルを併用した,TRAIL-R1アゴニスト単クローン抗体マパツムマブの無作為化第2相試験. Journal of Clinical Oncology. 28. 953. 1 indexed citations

Trarbach, Tanja, Markus Moehler, Volker Heinemann, et al.. (2010). Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. British Journal of Cancer. 102(3). 506–512. 150 indexed citations

Pawel, Joachim von, David R. Spigel, Mircea Dediu, et al.. (2010). A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.. Journal of Clinical Oncology. 28(18_suppl). LBA7501–LBA7501. 22 indexed citations

Eckhardt, S. Gail, G. Gallant, Branimir I. Šikić, et al.. (2010). Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2580–2580. 8 indexed citations

Huang, Xiaofeng, Michele Fiscella, Laurie Pukac, et al.. (2003). Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in diverse hematological tumor lines. Blood. 102(11). 89116. 5 indexed citations

Gallant, G., David M. Hilbert, Vivian R. Albert, et al.. (2003). New approaches for the treatment of multiple myeloma: targeting the B‐lymphocyte stimulator receptor and the tumor necrosis factor‐related apoptosis‐inducing ligand receptor. European Journal Of Haematology. 70(4). 267–267. 1 indexed citations

Sessa, Cristiana, Martin Highley, Olivia Pagani, et al.. (1999). Phase I study of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer. 35. S284–S284. 3 indexed citations

10.

Calvert, AH, Cristiana Sessa, Andrew Hughes, et al.. (1999). Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer. 35. S286–S286. 1 indexed citations

11.

Glück, Stefan, Colin Germond, Pedro López, et al.. (1998). A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. European Journal of Cancer. 34(7). 1008–1014. 19 indexed citations

12.

Warner, Ellen, Rajesh Kumar Goel, Warren Chow, et al.. (1998). A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). British Journal of Cancer. 77(12). 2376–2380. 26 indexed citations

13.

Shirazi, Farshad H., et al.. (1998). In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine.. Oncology Reports. 5(6). 1493–8. 3 indexed citations

14.

Bruera, Éduardo, Scott Ernst, Neil A. Hagen, et al.. (1998). Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.. PubMed. 2(2). 74–8. 76 indexed citations

15.

Stewart, Donald, Rajesh Kumar Goel, M. Christine Cripps, et al.. (1997). Concurrent use of multiple chemotherapy resistance modulators with etoposide in patients with resistant malignancies. International Journal of Oncology. 11(4). 709–16. 2 indexed citations

16.

Viallet, Jean, Ming‐Sound Tsao, & G. Gallant. (1996). Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines. Lung Cancer. 15(1). 93–101. 7 indexed citations

17.

Gallant, G., et al.. (1995). Synthesis and preliminary in vitro cytotoxicity evaluation of 1,3-bis-(2-propynyl)-1-nitrosourea (BPNU) and derivatives.. PubMed. 14(6B). 2695–9. 2 indexed citations

18.

Dulude, Hélène, et al.. (1995). In vitro cytotoxicity and differential cellular sensitivity of derivatives of diamino acids. I. N1-methyl, N1-allyl, N1-(2-chloroethyl) and N1-propargyl ureas.. PubMed. 15(3). 847–52. 2 indexed citations

19.

Gallant, G., et al.. (1993). In vitro cytotoxicity and differential cellular sensitivity of new N-methyl and N-propargyl urea and nitrosourea derivatives of diamino acids against sixty human NCI tumor cell lines.. PubMed. 13(1). 133–9. 3 indexed citations

20.

Gallant, G., et al.. (1991). Synthesis, anti-HIV and anti-Proliferative Activity of New Urea and Nitrosourea Derivatives of Amino Acids. Antiviral chemistry & chemotherapy. 2(5). 313–319. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact